Lopinavir/Ritonavir, commonly used for treatment of HIV infection, has been indicated for treatment of COVID‐19 in a number of reports (Kim et al., 2020). Previous studies suggested that when combined together, Lopinavir and Ritonavir act in concert to hinder further replication of SARS‐CoV, and improve the clinical status of patients with SARS (Chu et al., 2004). This might also mean that the well‐known antiretroviral duo can also prove beneficial in treatment of COVID‐19.